4.6 Article

Musashi1 Impacts Radio-Resistance in Glioblastoma by Controlling DNA-Protein Kinase Catalytic Subunit

期刊

AMERICAN JOURNAL OF PATHOLOGY
卷 186, 期 9, 页码 2271-2278

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.ajpath.2016.05.020

关键词

-

资金

  1. Cancer Prevention Research Institute of Texas (CPRIT) fellowship [RP140105]
  2. CPRIT Greehey fellowship [RP101491]
  3. Translational Science Training Across Disciplines Scholarship from the University of Texas System Graduate Programs Initiative
  4. National Cancer Institute [T32CA148724, 5T32CA148724-2]
  5. Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), Brazil
  6. NIH [K22ES012264, 1R15ES019128, 1R01CA152063]
  7. Max and Minnie Tomerlin Voelcker Fund [1R01HG006015-01A, 1R21CA175875-01A1]
  8. Institute for Integration of Medicine and Sciences (IIMS)-Cancer Therapy & Research Center (CTRC) (University of Texas Health Sciences Center at San Antonio)
  9. Voices Against Brain Cancer (VABC)

向作者/读者索取更多资源

The conserved RNA-binding protein Musashi1 (MSI1) has been characterized as a stem cell marker, controlling the balance between self-renewal and differentiation and as a key oncogenic factor in numerous solid tumors, including glioblastoma. To explore the potential use of MSI1 targeting in therapy, we studied MSI1 in the context of radiation sensitivity. Knockdown of MSI1 led to a decrease in cell survival and an increase in DNA damage compared to control in cells treated with ionizing radiation. We subsequently examined mechanisms of double-strand break repair and found that loss of MSI1 reduces the frequency of nonhomologous end-joining. This phenomenon could be attributed to the decreased expression of DNA protein kinase catalytic subunit, which we have previously identified as a target of MSI1. Collectively, our results suggest a role for MSI1 in double-strand break repair and that its inhibition may enhance the effect of radiotherapy.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据